BGM vs ESPR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ESPR Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Esperion Therapeutics, Inc. (ESPR) driven by superior Valuation, Growth & Margin, Options & Structure while BGM counters with relative strength in Momentum & Technical. Fundamentally, BGM trades at N/M Forward P/E with -23.4% operating margin (+69.8% YoY revenue) versus ESPR at 10.9x Forward P/E and -8.2% operating margin (+23.2% YoY). In options structure, BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ESPR sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BGM | ESPR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $108.6M | $822.0M | Larger Scale | ESPR |
| Trailing P/E Ratio Valuation | N/M | 4.6x | Lower Multiple | ESPR |
| Forward P/E Ratio Valuation | N/M | 10.9x | Lower Multiple | ESPR |
| Revenue Growth (YoY) Growth | +69.8% | +23.2% | Higher Growth | BGM |
| Operating Margin (TTM) Profitability | -23.4% | -8.2% | Higher Margin | ESPR |
| Net Profit Margin Profitability | -44.2% | -1.8% | Higher Margin | ESPR |
| Return on Equity (ROE) Capital Efficiency | -7.4% | -260.8% | Higher ROE | BGM |
| 52-Week Range Position Momentum | 74% ($0โ$11) | 68% ($1โ$4) | Stronger Trend | BGM |
| Beta / 30D Volatility Risk Regime | 3.69ฮฒ ยท 80% Vol | 1.86ฮฒ ยท 6% Vol | Lower Realized Risk | ESPR |
| Unified Institutional Score Composite Signal | 59.6 / 100 (HOLD) | 60.0 / 100 (BUY) | Higher Composite | ESPR |